![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals to Present at AACR-NCI-EORTC
14 oct. 2013 16h30 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals Responds to Further Misleading Claims Made by Sarissa Capital
09 oct. 2013 22h37 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), a pharmaceutical company dedicated to the discovery and development of novel small molecule...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals Announces Expiration of HSR Waiting Period for Pending Transaction
07 oct. 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), announced today that the waiting period for U.S. antitrust review under the Hart-Scott-Rodino...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals Issues Open Letter to Stockholders Regarding Otsuka Transaction
02 oct. 2013 19h40 HE
|
Astex Pharmaceuticals, Inc.
Astex Board of Directors Corrects the Record Regarding Recent Mischaracterizations
Urges Stockholders to Tender Shares into Otsuka Offer
DUBLIN, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- The...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress
30 sept. 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals Withdraws From Upcoming Investor Conferences
06 sept. 2013 18h45 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash
05 sept. 2013 03h48 HE
|
Astex Pharmaceuticals, Inc.
TOKYO and DUBLIN, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. ("Otsuka") and Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), announced today that their respective...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals to Present at Investor Conferences in September
03 sept. 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study
28 août 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) today announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase...
![Astex Pharmaceuticals, Inc. logo](/news-release/logo/213737/0/213737.jpg?lastModified=12%2F09%2F2016%2023%3A12%3A02&size=2)
Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results
01 août 2013 08h00 HE
|
Astex Pharmaceuticals, Inc.
SGI-110 Clinical Data Presented at EHA for Phase 1 MDS Patients
Second Quarter Royalty Revenue Increased 15% to $16.6 Million
Royalty Revenue Guidance Revised From $55 Million to $63 Million for...